Current Document Type: HighlightsVideoPage Mechanisms of Resistance to Anti-HER2 Therapy for Metastatic Breast Cancer - JADPRO

Watch More Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses a genomic analysis of 733 HER2-positive breast cancers, which identified recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities. The findings may help clinicians identify selective strategies to prevent disease progression (Abstract GS3-03).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.